haematology Flashcards
treatment for hodgkin’s lymphoma
chemotherapy
reed-sternberg cells
hodgkin’s lymphoma
when to offer platelet transfusion in someone with clinically significant bleeding
platelet count of <30 x 10 9
when to offer platelet transfusion in someone with clinically significant bleeding at critical sites such as CNS
maximum < 100 x 10 9
what blood product has the highest risk of bacterial contamination
platelets
DOAC reversal agent
andexanet alfa
Howell-Jolly bodies
hyposplenism (reduced spleen function)
hypersegmented neutrophils, oval macrocytes
megaloblastic macrocytic anaemia
h.pylori and lymphoma
MALToma
smear/smudge cells
CLL
philadelphia chromosome
t(9:22)
CML
treatment for CML
imatnib
aquagenic puritis
polycythaemia vera
auer rods
AML
BCR-ABL1 positive myeloproliferative neoplasms
CML
BCR-ABL1 negative myeloproliferative neoplasms
polycythaemia vera
essential thrombocytopenia
primary myelofibrosis
gene associated with polycythaemia vera
JAK2
treatment of polycythaemia vera
chemotherapy (hydroxycarbamide)
venesection
aspirin
what is essential thrombocythaemia
myeloproliferative neoplasm causing increased number of platelets
what is polycythaemia vera
myeloproliferative neoplasm causing increased number of RBCs
prognosis in myeloproliferative diseases
uncurable
PV: The 5 year survival rate for PV patients is 85%
ET: The 5 year survival is equivalent to matched, healthy people
Primary myelofibrosis: at 5 years, the survival rate is 55% (median survival is 4-5 years)
blood film in primary myelofibrosis
leucoerythroblastic
treatment of primary myelofibrosis
supportive
JAK2 inhibitors (ruxolitinib)
allogenic stem cell
chemotherapy
blast crisis in CML
transformation to AML